Sanofi to acquire Bioverativ for $11.6 billion
PARIS — Sanofi plans to buy biopharmaceutical company Bioverativ Inc. in a deal valued at $11.6 billion. Waltham, Mass.-based Bioverativ specializes in therapies for hemophilia and other rare blood disorders. Sanofi said Monday that the addition of Bioverativ will boost its presence in specialty care and leadership in rare diseases as well as provide an expansion platform
